HR 6344, the Simon Crosier Act, requires Medicare and Medicaid providers to establish written policies for do-not-resuscitate (DNR) orders involving unemancipated minors (under 18 without legal independence). It mandates that providers must inform at least one parent or legal guardian in person or by phone (with 72 hours of effort) before considering a DNR, allow parents/guardians to refuse consent, and prohibit overriding parental objections to life-sustaining treatment. The bill also requires providers to continue life-sustaining care for 15 days if a parent requests a transfer and explicitly prohibits using disability as the sole basis for DNR decisions. These requirements apply to all Medicare/Medicaid-covered facilities and directly affect minors, their parents, and healthcare providers.
HR 6177 prohibits federal funding from the Department of Health and Human Services (HHS) for researchers involved in studies or experiments involving minors that: (1) affirm a minor's gender identity differing from their sex assigned at birth, (2) provide medical/surgical services to help minors disassociate from their biological sex, or (3) use social interventions for the same purpose. The bill directly affects researchers seeking HHS grants for such studies, requiring them to certify they have never led such projects. It defines "sex" biologically at birth (based on reproductive biology and genetics) and "minor" as anyone under 18. The law bans funding for any federally-supported research meeting these criteria, regardless of the study's focus.
This bill prohibits the Department of Health and Human Services from finalizing, implementing, or enforcing the proposed "Safe and Appropriate Foster Care Placement Requirements for Titles IV-E and IV-B" rule (published September 28, 2023). It directly affects federal foster care programs by blocking a specific rule that would have required states to consider religious beliefs when placing children in foster care. The key mechanism is a clear statutory ban on the rule's implementation, preventing it from taking effect. The bill does not create new requirements but stops the enforcement of this particular federal regulation.
The Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.
# Summary of the Proposed "States Reform Act"
This comprehensive federal legislation proposes to comprehensively reform U.S. cannabis policy by:
1. **Decriminalizing and regulating cannabis**: Removing cannabis from Schedule I of the Controlled Substances Act and establishing a federal regulatory framework similar to alcohol regulation.
2. **Creating a regulatory structure**:
- Establishing a federal excise tax of 3% on cannabis products
- Creating categories for different cannabis products (flower, pre-rolls, extracts, etc.)
- Implementing packaging, labeling, and safety requirements
- Establishing a certification process for designated State medical cannabis products
3. **Medical cannabis provisions**:
- Creating a process for FDA to certify medical cannabis products
- Allowing for specific medical indications (arthritis, nausea, pain, PTSD, etc.)
- Permitting State medical cannabis programs to operate under federal framework
- Creating a "Law Enforcement Retraining and Successful Second Chances Fund" (30% of tax revenue)
4. **Business and economic provisions**:
- Removing barriers for cannabis-related businesses to access SBA loans
- Establishing "cannabis-related legitimate business" definitions
- Creating new reporting requirements for the cannabis industry
- Mandating demographic data collection on cannabis industry workers
5. **Veterans' access**:
- Prohibiting federal employment discrimination against veterans who use medical cannabis
- Allowing VA health providers to discuss State-approved medical cannabis programs with veterans
6. **Other key provisions**:
- Establishing a "cannabis" term to replace "marijuana" or "marihuana" in all federal law
- Allowing veterans to have security clearances reconsidered if denied for cannabis use
- Creating international trade policy for cannabis
- Mandating continued federal drug testing for employees in certain positions
- Establishing a 10-year moratorium on increasing cannabis excise tax
The bill would establish a comprehensive federal framework for legal cannabis that would operate alongside existing State programs, with detailed tax, regulatory, and reporting requirements. It would also include significant provisions to address social equity, veterans' access, and economic opportunities in the emerging cannabis industry.
The Revoke Iranian Funding Act of 2023 would cancel all existing U.S. licenses and exemptions allowing funds to be released to Iran for humanitarian purposes, including a $6 billion transfer from South Korea. It also rescinds a specific waiver issued in September 2023 that permitted such transfers. The bill requires the Treasury to submit a 30-day report to Congress detailing Iranian assets blocked by the U.S. and current sanctions exemptions related to Iran. This legislation directly restricts U.S. financial access for Iran and its designated entities, aiming to prevent funds from being diverted to support terrorism.
HR 5967, the Unemployment Integrity Act of 2023, requires unemployment claimants to participate in job-seeking activities to maintain benefits. Specifically, it mandates that claimants respond to work-related requests, attend reemployment interviews, and comply with reasonable requests like drug testing or skills assessments. The bill also requires states to conduct a study on increasing random audits of unemployment claims and mandates that states adopt these new requirements to receive federal funds for extended unemployment benefits. These changes apply to weeks beginning one year after the bill's enactment, with adjustments for states holding biennial legislative sessions. The law directly affects individuals claiming unemployment benefits by linking eligibility to active job-seeking participation.
This bill, titled "Freezing HAMAS Act" (though it concerns Iran sanctions, not Hamas), reinstates U.S. sanctions on Iran that were previously waived or suspended under agreements with Iran. It specifically targets sanctions from the 2012 Iran Freedom and Counter-Proliferation Act and the 2012 National Defense Authorization Act, including a September 2023 waiver related to fund transfers. The bill prohibits the U.S. government from releasing funds or assets to Iran or granting further waivers related to these sanctions. It directly affects U.S. government actions regarding Iran financial transactions and enforcement of existing sanctions.
HR 5840, the Transportation Security Screening Modernization Act of 2024, simplifies the process for transportation workers to obtain multiple TSA security credentials. It requires the TSA to allow individuals to apply for and renew programs like the TWIC (Transportation Worker Identification Credential) and HAZMAT Endorsement through a single enrollment at any TSA center, with a combined fee lower than separate applications. The bill mandates coordinated expiration dates for all credentials and ensures state-issued commercial driver's licenses reflect the correct HAZMAT endorsement validity. These changes aim to reduce duplication and costs for workers needing multiple security clearances. The TSA must implement these changes within two years and publish details online.
This bill, HR 5796, prohibits the Department of Health and Human Services from implementing a proposed rule requiring minimum staffing levels in nursing homes. It creates an advisory panel of 15 members - including rural nursing home staff and experts - to study workforce shortages and report on access barriers for seniors, especially in rural areas. The panel must submit an initial report within 60 days, analyzing staffing challenges and recommending solutions to strengthen the nursing home workforce. These provisions directly aim to prevent nursing home closures (like the 129 that occurred in 2022) that threaten rural seniors’ access to care.
HR 5713, the Homeland Security Fentanyl Enforcement Act, authorizes Homeland Security Investigations (HSI) agents and designated state/local officers to enforce drug laws related to fentanyl trafficking under the Controlled Substances Act for five years. It requires the Government Accountability Office (GAO) to review and report on coordination between the Drug Enforcement Administration (DEA) and HSI in drug investigations within 18 months, including whether investigations followed established coordination policies. The bill mandates the Homeland Security Secretary and Attorney General to address any coordination failures found in the GAO report, prioritizing existing interagency task forces. This bill focuses on improving interagency coordination to combat fentanyl smuggling by transnational criminal organizations, without altering DEA's core authorities or creating new drug penalties.
This bill requires health insurance plans (both private and Medicare) to cover routine patient costs for children with rare pediatric diseases participating in approved clinical trials, even when care is provided by non-network providers. Specifically, it mandates that insurers apply the same copay or coinsurance rate for non-participating providers as they would for in-network providers during clinical trial participation. The law expands the definition of "routine costs" to include consultation and referral services related to these trials and updates Medicare coverage rules to align with this requirement. These changes apply to plans beginning January 1, 2024, directly affecting families of children with rare pediatric cancers enrolled in qualifying clinical trials.
